FGEN FibroGen Inc.

FibroGen to Present at Upcoming Investor Conferences

FibroGen to Present at Upcoming Investor Conferences

SAN FRANCISCO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences:

  • 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021 at 3:40 PM Eastern Time
  • Cowen 41st Annual Health Care Conference on March 2, 2021 at 12:50 PM Eastern Time

A live audio webcast will be available on the “Events & Presentations” section of the FibroGen Investor webpage at A replay will be available for approximately 30 days.

About FibroGen

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). For more information, please visit

Contact:

FibroGen, Inc.

Investors:

Michael Tung, M.D.

Corporate Strategy / Investor Relations

1.415.978.1434

Media:

Jennifer Harrington

+1.610.574.9196



EN
12/02/2021

Underlying

FGENFibroGen Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FibroGen Inc.

 PRESS RELEASE
Free
FGEN FIBROGEN INC.

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Co...

Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. Thane Wettig, Chief Executive Officer of Kyntra Bio, will deliver a company presentation on Monday, April 13, 2026, at 1:30 PM EDT. A live webcast of the presentation will be available . Kyntra Bio’s management team will be available for one-on-one meetings during the conference. Interested investors sho...

April 8, 2026 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results...

Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for interim analysis in 2H 2026Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC, further validating key Phase 2 monotherapy design elements, were presented at the 2026 ASCO GUSubmitted the pivotal Phase 3 clinic...

March 16, 2026 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Resul...

Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to...

March 9, 2026 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Pha...

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who prog...

February 23, 2026 1 EN
 PRESS RELEASE
Free
FGEN FIBROGEN INC.

Kyntra Bio to Participate in Upcoming Investor Conferences

Kyntra Bio to Participate in Upcoming Investor Conferences SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the company’s management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation Date & Time: Thursday, February 26, 2026, 2:40-3:10 PM ET Location: Virtual Webcast: Leerink Global Healthcare ConferenceFormat: Corporate Presentation Date & Time: Wednesday, March 11, 2026, 2:20-2:50 PM ETLocation: Miami, FL Webc...

February 17, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch